These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 36078036)

  • 1. The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex.
    Palmas MF; Etzi M; Pisanu A; Camoglio C; Sagheddu C; Santoni M; Manchinu MF; Pala M; Fusco G; De Simone A; Picci L; Mulas G; Spiga S; Scherma M; Fadda P; Pistis M; Simola N; Carboni E; Carta AR
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
    Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
    Palmas MF; Ena A; Burgaletto C; Casu MA; Cantarella G; Carboni E; Etzi M; De Simone A; Fusco G; Cardia MC; Lai F; Picci L; Tweedie D; Scerba MT; Coroneo V; Bernardini R; Greig NH; Pisanu A; Carta AR
    Neurotherapeutics; 2022 Jan; 19(1):305-324. PubMed ID: 35072912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study.
    Manchinu MF; Pala M; Palmas MF; Diana MA; Maschio A; Etzi M; Pisanu A; Diana FI; Marongiu J; Mansueto S; Carboni E; Fusco G; De Simone A; Carta AR
    Exp Neurol; 2024 Feb; 372():114651. PubMed ID: 38092188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson's Disease.
    Murgia F; Atzori L; Carboni E; Santoru ML; Hendren A; Pisanu A; Caboni P; Boi L; Fusco G; Carta AR
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
    Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
    Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
    Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
    J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
    Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
    J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
    Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
    Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
    Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The angiotensin (1-7) glycopeptide PNA5 improves cognition in a chronic progressive mouse model of Parkinson's disease through modulation of neuroinflammation.
    Bernard K; Mota JA; Wene P; Corenblum MJ; Saez JL; Bartlett MJ; Heien ML; Doyle KP; Polt R; Hay M; Madhavan L; Falk T
    Exp Neurol; 2024 Nov; 381():114926. PubMed ID: 39153685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice.
    Rocha SM; Bantle CM; Aboellail T; Chatterjee D; Smeyne RJ; Tjalkens RB
    Neurobiol Dis; 2022 Jun; 167():105685. PubMed ID: 35257879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
    Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
    J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Ca
    Leandrou E; Chalatsa I; Anagnostou D; Machalia C; Semitekolou M; Filippa V; Makridakis M; Vlahou A; Anastasiadou E; Vekrellis K; Emmanouilidou E
    Transl Neurodegener; 2024 Feb; 13(1):11. PubMed ID: 38378800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
    Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
    Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.